|M14738||NCT-502||NCT-502 is a human phosphoglycerate dehydrogenase (PHGDH) inhibitor, cytotoxic to PHGDH-dependent cancer cells, and reduces glucose-derived serine production, with an IC50 of 3.7 μM against PHGDH.|
|M14661||BI-4924||BI-4924 is a lipophilic, highly plasma protein bound selective phosphoglycerate dehydrogenase (PHGDH) inhibitor (IC50=3 nM) with excellent microsomal, as well as hepatocytic stability.|
|M14660||BI-4916||BI-4916 is a prodrug of BI-4924. BI-4924 is a NADH/NAD+-competitive PHGDH inhibitor.|
|M8604||NCT-503||NCT-503 is an inhibitor of phosphoglycerate dehydrogenase (PHGDH), which catalyzes the first, rate-limiting step of glucose-derived serine synthesis.|
|M6566||CBR 5884||CBR 5884 is a 3-Phosphoglycerate dehydrogenase (PHGDH) inhibitor.|
|M29874||PKUMDL-WQ-2101||PKUMDL-WQ-2101 is a non-NAD+-competing allosteric phosphoglycerate dehydrogenase (PHGDH) inhibitor with an IC50 of 34.8 μM. PKUMDL-WQ-2101 exhibits antitumor activity.|
|M29015||PHGDH-inactive||PHGDH-inactive has no activity against PHGDH and serves as a negative control of NCT-502 and NCT-503.|
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2023 AbMole BioScience. All Rights Reserved.